Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide
Conclusion:PADI4, SDF4, and TP53INP1 are novel therapy and biomarker candidates for GBM. Further investigation of their oncologic functions may provide new insight into GBM treatment resistance mechanisms. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - December 18, 2023 Category: Genetics & Stem Cells Source Type: research
Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study
ConclusionsTMZ proved to be a secure treatment with no negative side effects on cognition and on level of daily autonomy, even at the highest dosage used. This is a positive finding which enables clinicians to reassure patients about the absence of significant negative effects of TMZ on their daily life functioning. In this view, eventual cognitive changes during treatment might not be attributed to chemotherapy but to other events such as tumour relapse. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 18, 2023 Category: Cancer & Oncology Source Type: research
Malignant gastrointestinal neuroectodermal tumor: a case report and literature review
CONCLUSION: Containing apatinib may provide an additional treatment option for patients with chemotherapy-resistant GNET tumors.PMID:38098564 | PMC:PMC10718339 | DOI:10.1097/MS9.0000000000001400 (Source: Annals of Medicine)
Source: Annals of Medicine - December 15, 2023 Category: Internal Medicine Authors: Dan Su Hujuan Yang Ming Zhao Hongying Zhou Jin Wu Zhongkuo Zhao Jianguo Zhong Qian Xue Yupeng Hong Jie Sun Xiaoyi Li Tongwei Zhao Source Type: research
Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial
DiscussionThe addition of CPZ to standard TMZ in the first-line treatment of GBM patients with unmethylated MGMT gene promoter was safe and led to a longer PFS than expected in this population of patients. These findings provide proof-of-concept for the potential of adding CPZ to standard TMZ treatment in GBM patients with unmethylated MGMT gene promoter.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04224441, identifier NCT04224441. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - December 14, 2023 Category: Cancer & Oncology Source Type: research
Preferential MGMT hypermethylation in SDH-deficient wild-type GIST
Conclusion
MGMT promoter hypermethylation occurs exclusively in a subset of dSDH wtGIST. Data from this study support testing of tumour MGMT promoter methylation in patients with dSDH wtGIST to identify those patients who may benefit from most from TMZ therapy. (Source: Journal of Clinical Pathology)
Source: Journal of Clinical Pathology - December 14, 2023 Category: Pathology Authors: Giger, O. T., ten Hoopen, R., Shorthouse, D., Abdullahi, S., Bulusu, V. R., Jadhav, S., Maher, E. R., Casey, R. T. Tags: Open access Original research Source Type: research
Neuro-oncology Treatment Strategies for Primary Glial Tumors
Semin Neurol 2023; 43: 889-896 DOI: 10.1055/s-0043-1776764Primary brain tumors underwent reclassification in the 2021 World Health Organization update, relying on molecular findings (especially isocitrate dehydrogenase mutations and chromosomal changes in 1p, 19q, gain of chromosome 7 and loss of chromosome 10). Newer entities have also been described including histone 3 mutant midline gliomas. These updated pathologic classifications improve prognostication and reliable diagnosis, but may confuse interpretation of prior clinical trials and require reclassification of patients diagnosed in the past. For patients over seven...
Source: Seminars in Neurology - December 14, 2023 Category: Neurology Authors: Santos-Pinheiro, Fernando Graber, Jerome J. Tags: Review Article Source Type: research
An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma
ConclusionGermline SDHB mutations can rarely cause PA in the absence of PPGL. They should be considered as a possible cause of aggressiveness and resistance to dopamine agonists in similar cases. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 13, 2023 Category: Endocrinology Source Type: research
Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells
Cell Death Discov. 2023 Dec 12;9(1):451. doi: 10.1038/s41420-023-01738-x.ABSTRACTSphingolipid metabolism is dysregulated in many cancers, allowing cells to evade apoptosis through increased sphingosine-1-phosphate (S1P) and decreased ceramides. Ceramidases hydrolyze ceramides to sphingosine, which is phosphorylated by sphingosine kinases to generate S1P. The S1P allows cells to evade apoptosis by shifting the equilibrium away from ceramides, which favor cell death. One tumor type that exhibits a shift in the sphingolipid balance towards S1P is glioblastoma (GBM), a highly aggressive brain tumor. GBMs almost always recur de...
Source: Cancer Control - December 12, 2023 Category: Cancer & Oncology Authors: Cyntanna C Hawkins Amber B Jones Emily R Gordon Yuvika Harsh Julia K Ziebro Christopher D Willey Corinne Griguer David K Crossman Sara J Cooper Sasanka Ramanadham Ninh Doan Anita B Hjelmeland Source Type: research
GSE249155 Single ‑nucleotide resolution mapping reveals profiles of O6‑methylguanine formation and repair in a glioblastoma cell line exposed to temozolomide
Contributors : Jasmina B üchel ; Cécile Mingard ; Vakil Takhaveev ; Patricia B Reinert ; Giulia Keller ; Tom Kloter ; Sabrina M Huber ; Maureen McKeague ; Shana J SturlaSeries Type : OtherOrganism : Homo sapiensTemozolomide kills cancer cells by forming O6 methylguanine (O6 MeG), which leads to apoptosis by mismatch-repair overload. However, O6 MeG can be repaired by O6 methylguanine-DNA methyltransferase (MGMT), causing drug resistance. The current lack of methods to map genomic profiles of O6 ‑MeG impedes the application of temozolomide in personalized medicine. Here, we devised a immunoprecipitation- and polym...
Source: GEO: Gene Expression Omnibus - December 12, 2023 Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
Retraction: CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
J Cell Mol Med. 2023 Dec 10. doi: 10.1111/jcmm.18078. Online ahead of print.ABSTRACTYingxiao Cao, Xin Li, Shiqi Kong, Shuling Shang, Yanhui Qi. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 2020; 24: 5135-5145. https://doi.org/10.1111/jcmm.15156. The above article, published online on 11 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Stefan Constantinescu, The Foundation for Cellular and Molecular Medicine, and John Wiley and Sons Ltd. The retraction has been ...
Source: Molecular Medicine - December 11, 2023 Category: Molecular Biology Source Type: research
Retraction: CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
J Cell Mol Med. 2023 Dec 10. doi: 10.1111/jcmm.18078. Online ahead of print.ABSTRACTYingxiao Cao, Xin Li, Shiqi Kong, Shuling Shang, Yanhui Qi. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 2020; 24: 5135-5145. https://doi.org/10.1111/jcmm.15156. The above article, published online on 11 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Stefan Constantinescu, The Foundation for Cellular and Molecular Medicine, and John Wiley and Sons Ltd. The retraction has been ...
Source: J Cell Mol Med - December 11, 2023 Category: Molecular Biology Source Type: research
Retraction: CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
J Cell Mol Med. 2023 Dec 10. doi: 10.1111/jcmm.18078. Online ahead of print.ABSTRACTYingxiao Cao, Xin Li, Shiqi Kong, Shuling Shang, Yanhui Qi. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 2020; 24: 5135-5145. https://doi.org/10.1111/jcmm.15156. The above article, published online on 11 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Stefan Constantinescu, The Foundation for Cellular and Molecular Medicine, and John Wiley and Sons Ltd. The retraction has been ...
Source: Molecular Medicine - December 11, 2023 Category: Molecular Biology Source Type: research
Retraction: CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
J Cell Mol Med. 2023 Dec 10. doi: 10.1111/jcmm.18078. Online ahead of print.ABSTRACTYingxiao Cao, Xin Li, Shiqi Kong, Shuling Shang, Yanhui Qi. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 2020; 24: 5135-5145. https://doi.org/10.1111/jcmm.15156. The above article, published online on 11 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Stefan Constantinescu, The Foundation for Cellular and Molecular Medicine, and John Wiley and Sons Ltd. The retraction has been ...
Source: J Cell Mol Med - December 11, 2023 Category: Molecular Biology Source Type: research
